A Study of NCS-01 in Patients With Acute Ischemic Stroke

Summary

This is an initial Phase1/2 dose-finding, randomized, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 48 hours of stroke onset. This study will be conducted in 2 stages.

Timeline

Start

2020-02-27

Primary completion

2027-10

Completion

2028-10

Drugs

Indications